Clinical trials: Chronic Nonmalignant Pain
Chronic Non-malignant Pain
Pain Program for Active Coping & Training
The overall aim of this study is to adopt an integrative rehabilitation approach for helping patients adopt self-management skills for managing chronic pain, limiting use of opioid medications, and identifying exacerbating…
- Trial name
- PPACT (NCT02113592)
- Testing
- Interdisciplinary pain program
- Where
- 3 sites in United States
- Volunteers
- 850 people
- Sponsor
- Kaiser Permanente
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.
Opioid-Induced Constipation
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in…
- Trial name
- NCT01186770
- Testing
- Methylnaltrexone
- Where
- 2 sites in United States
- Volunteers
- 804 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Non-malignant Pain, Chronic Pain
Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain
This is a prospective, multi-center, post market study to evaluate Intrathecal (IT) preservative-free morphine sulfate (PFMS) using the SynchroMed™ II infusion system as an alternative to systemic opioids for the treatment of…
- Conditions
- Chronic Non-malignant Pain, Chronic Pain, Pain, Back, Pain, Leg
- Trial name
- NCT03761277
- Testing
- Medtronic SynchroMed™ II infusion system, Preservative-free morphine sulfate (PFMS)
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- MedtronicNeuro
Chronic Nonmalignant Pain
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
The objective of this study was to evaluate the long-term safety and tolerability of 7-day BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain syndromes whose pain had been previously…
- Trial name
- NCT01151098
- Testing
- Buprenorphine transdermal patch
- Where
- 19 sites in United States
- Volunteers
- 189 people
- Sponsor
- Purdue Pharma LP
Chronic Nonmalignant and Nonneuropathic Pain
Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.
- Trial name
- NCT01400139
- Testing
- Hydrocodone bitartrate q24h film-coated tablets
- Where
- 98 sites in United States
- Volunteers
- 922 people
- Sponsor
- Purdue Pharma LP
Pain, Osteoarthritis
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a…
- Conditions
- Pain, Osteoarthritis, Low Back Pain
- Trial name
- NCT00487435
- Testing
- Tapentadol (CG5503) Extended Release (ER)
- Where
- 148 sites in United States, Australia and 2 more
- Volunteers
- 1,166 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Opioid-induced Constipation
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.
- Trial name
- NCT01443403
- Testing
- Naldemedine
- Where
- 49 sites in United States
- Volunteers
- 244 people
- Sponsor
- Shionogi
Chronic Pain
An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)
Objectives: 1. Objective of main interest To assess the drop-out rate caused by adverse event* after 6 weeks treatment 2. Further objectives To assess the drop-out rate caused by adverse event* after 1 week treatment To assess…
- Trial name
- NCT01811186
- Testing
- Oxycodone/naloxone
- Where
- South Korea
- Volunteers
- 261 people
- Sponsor
- Mundipharma Korea Ltd
Chronic Non-malignant Pain
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal system in subjects with chronic nonmalignant…
- Trial name
- NCT00312195
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States, United Kingdom
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Opioid-induced Constipation
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
- Trial name
- NCT01965158
- Testing
- Naldemedine
- Where
- 65 sites in United States, Austria and 5 more
- Volunteers
- 547 people
- Sponsor
- Shionogi
Chronic Pain
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN…
- Trial name
- NCT02880475
- Testing
- OXN PR tablet
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Pain
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s) every 12 hours.
- Trial name
- NCT00765856
- Testing
- Oxymorphone ER
- Where
- 13 sites in United States
- Volunteers
- 27 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Chronic Pain
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain
The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl patch (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01816243
- Testing
- TTS-Fentanyl, Morphine
- Where
- 2 sites in Thailand
- Volunteers
- 39 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Opioid-induced Constipation
Long Term Safety of Naldemedine
The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.
- Trial name
- NCT01965652
- Testing
- Naldemedine
- Where
- 186 sites in United States, Australia and 14 more
- Volunteers
- 1,246 people
- Sponsor
- Shionogi
Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
- Trial name
- NCT00415597
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Where
- 58 sites in United States
- Volunteers
- 467 people
- Sponsor
- Pfizer
Constipation
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to…
- Trial name
- NCT00547586
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 41 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain…
- Trial name
- NCT00605644
- Testing
- MOA-728
- Volunteers
- 128 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.